SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media shares are under pressure as traders connect the decline to Trumps reported record-low approval and approaching midterms, while also questioning the companys business fundamentals. Some see the selloff as a speculative buying opportunity, but bearish sentiment dominates.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is drawing attention amid a sharp selloff and mounting concern over its heavy debt, costly financing, and ability to fund AI infrastructure expansion. Bears see refinancing and dilution risks outweighing its AI demand and backlog, while bulls point to those growth prospects and dip buying; a bullish analyst call and ARK purchases have not quelled the debate.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO selloff is the dominant topic, with traders pointing to lockup-related share supply, reported insider selling and a TD Cowen price-target cut, alongside concerns about valuation and the companys ability to scale. Sentiment is largely bearish, though some investors view the decline as oversold and are adding to positions.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Ubers prolonged share-price weakness is driving debate over whether robotaxi competition from Waymo and Tesla threatens its rides business, or whether that risk is overstated given its scale and cash generation. Some traders view the shares as undervalued and welcome the ezCater deal as a boost to delivery, while others remain frustrated by the stocks persistent underperformance.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Anktivas FDA label expansion into papillary-only bladder cancer is the main catalyst, but IBRX has sold off despite the approval and positive trial updates. Bulls characterize the decline as a sell-the-news move or short pressure, while skeptics point to valuation, competition, and the need for revenue growth to support the companys expectations.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians prolonged slide to fresh 52-week lows is driving discussion, with traders focused on concerns about cash burn, execution and the R2 production ramp ahead of Q3 earnings, despite stronger deliveries. Some are buying the dip and pointing to R2 progress and VW backing, while others question profitability and whether upcoming results can change sentiment.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSparks steep selloff alongside other bitcoin miners is driving discussion, with traders pointing to financing and debt costs, higher rates, and weak sector sentiment. Bulls argue the Meta-backed AI data-center lease and bitcoin holdings offer longer-term support, while skeptics say those positives have not offset near-term risks or the stocks underperformance.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

VICR is drawing attention ahead of its quarterly earnings report, with traders weighing expectations for strong results against the stocks history of sharp post-earnings moves. Bulls point to recent guidance increases tied to royalties from its AI-related Vertical Power Delivery technology, while others flag uncertainty around the results and costly options positioning.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Attention centers on the anticipated completion of Compass Pathways rolling FDA application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and the potential path toward approval and commercialization. Many traders see the regulatory milestone as a catalyst, while others are frustrated by the share-price weakness and uncertainty over the submission timeline and eventual FDA decision.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Traders are focused on the administration weighing temporary permission for compounding pharmacies to sell certain restricted peptides, which could create a new opportunity for Hims & Hers but is not a finalized approval. The community sees potential upside from a peptide launch, while skeptics point to recurring failed rallies and continued range-bound trading.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Large Increase in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 70,605 shares, a growth...

Q1 Earnings Estimate for DWTX Issued By Zacks Research

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Free Report) - Equities researchers at Zacks Research issued their Q1 2026 EPS estimates for Dogwood Therapeutics in a research note issued to investors on...

Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday

Dogwood Therapeutics (NASDAQ:DWTX) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-dogwood-therapeutics-inc-stock...

HC Wainwright Issues Positive Forecast for DWTX Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 EPS estimates for shares of Dogwood Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst S. Lee now expects that the company will post earnings per share of...

What is HC Wainwright's Estimate for DWTX FY2030 Earnings?

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Free Report) - Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Dogwood Therapeutics in a research...

Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Decreases By 15.1%

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Get Free Report) saw a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 56,171 shares, a...

Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7% - Time to Buy?

Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7% - Time to Buy...

What's Driving the Market Sentiment Around Dogwood Therapeutics Inc?

DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence

Equity

The company said that Halneuron demonstrated separation from placebo treated patients in terms of pain improvement but did not detail the scale of the said improvement. 


Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug 

In return for the license, Sepin Pharma and its designated affiliates will get 7.31% of Dogwood’s common stock, on a fully diluted basis.


Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Dogwood Therapeutics Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>Dogwood also reported a study dropout rate of 4.4%, which the company said is far below rates typically observed with other FDA approved chronic pain medicines.</li><li>The company expects to have top-line results from the trial available during the third quarter (Q3) of 2026.&nbsp;</li><li>Last month, Dogwood said that it has cash on hand of $10.1 million, providing operational runway only through the first quarter of 2026.</li></ul>Dogwood Therapeutics, Inc. (DWTX) said on Monday that patients with chemotherapy induced neuropathic pain (CINP) treated with its painkiller Halneuron demonstrated separation from placebo treated patients in terms of pain improvement over a four-week study. &nbsp;Shares of the company fell 22% at the time of writing and is now poised to log its worst day in over nine months as the update failed to boost investor sentiment.The separation in pain improvement was identified by an independent statistical review committee who reviewed patient treatment data from a mid-stage trial under which 97 patients have completed treatment so far. The company did not <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/12/22/3209363/0/en/Dogwood-Therapeutics-Announces-Positive-Interim-Phase-2b-Clinical-Trial-Results-in-Chemotherapy-Induced-Neuropathic-Pain.html">detail </a>the scale of pain improvement observed in the analysis.The company expects to have top-line results available during the third quarter (Q3) of 2026.Dogwood also reported a study dropout rate of 4.4%, which the company said is far below rates typically observed with other FDA approved chronic pain medicines.<h2 class="st-heading-2">Company Sounds Optimism</h2>According to Dogwood, current study patient enrollment trends are projected to provide statistical power of approximately 80% to 85% to detect a Halneuron treatment difference.“Extrapolation of the current Phase 2b study trends has the potential to represent the first statistically significant trial involving CINP patients under FDA chronic pain study guidance,” said CEO Greg Duncan.Halneuron is Dogwood’s lead product candidate and has been granted fast track designation from the FDA for the treatment of CINP. Last month, the company confirmed enrollment of 100 patients in the mid-stage study for Halneuron. The company is targeting enrolling 200 patients in the study in total.“We are hopeful that positive outcomes in this ongoing Phase 2b trial will set the stage for a Phase 3 registration program in CINP, providing a needed therapeutic option for this patient population of cancer survivors,” Chief Medical Officer Michael Gendreau said on Monday.<h2 class="st-heading-2">Limited Operational Runway</h2>Last month, Dogwood said that it has cash on hand of $10.1 million, providing operational runway only through the first quarter of 2026, before it can announce the results of the ongoing Halneuron trial. &nbsp;The company reported a third quarter basic and diluted net loss per share of $8.20, compared to an analyst estimate of a loss of $1.58 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around DWTX fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.A Stocktwits user now expects the stock to drop as low as $2.<stembedurl>https://www.stocktwits.com/hammerfall43/message/639878419</stembedurl><a href="https://stocktwits.com/symbol/DWTX">DWTX stock</a> has nearly doubled this year. &nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-hits-record-high-as-elon-musk-hints-at-fsd-launch-in-uae-next-month-amid-2018-pay-package-boost/cLeFNmTREMq">Tesla Stock Hits Record High As Elon Musk Hints At FSD Launch In UAE Next Month Amid 2018 Pay Package Boost</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

The company said that Halneuron demonstrated separation from placebo treated patients in terms of pain improvement but did not detail the scale of the said improvement. 

Vanguard Extended Market ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Stocktwits

SpaceX

Netflix Inc

Meta Platforms Inc

Which earnings release are you most looking forward to this week: 

Stocktwits Polls

$DWTX Halneuron Phase 2b top line data release next month. There are currently no FDA approved treatments for CINP (chemotherapy-induced neuropathic pain) which makes this tempting. Old school $VIRI crew @The1Albatross  👊

Enrico Palazzo

$DWTX offered a private placement of 4,098,360 shares at $1.22 each, generating roughly $5 million for working capital.

jorge .miguel

$DWTX who knows here. Private placement for cash to accelerate phase 3. It’s at 1.22, maybe they run her?

Tamu Massif

$DWTX geez I have not looked at this thing in a while.  $1.50 , $50M MC, 10M float... whats the catalyst/play here? Chart looks lovely!

Sage

$DWTX 💰 

Dogwood Therapeutics, Inc. entered into a subscription agreement with Sealbond Limited to sell 4,098,360 shares in a private placement at $1.22 per share for expected gross proceeds of approximately $5 million for general working capital. 

Curated for market relevance

Rayvio | Market News Filter

$DWTX Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

DWTX Dogwood Therapeutics Inc.

Fundamentals

Latest DWTX News